Literature DB >> 29955023

Modified TALK Score for Japanese Patients with Laryngeal and Hypopharyngeal Cancers to Predict the Possibility of Laryngeal Preservation by Concurrent Chemoradiotherapy.

Naoki Otsuki1, Mio Matsui2, Miki Takahashi1, Ryohei Sasaki3, Naomi Kiyota4, Makoto Usami5, Ken-Ichi Nibu1.   

Abstract

OBJECTIVE: TALK score has been developed as an index for predicting the possibility of larynx preservation and prognosis of the patients with advanced laryngeal and hypopharyngeal cancers treated by concurrent chemoradiotherapy (CCRT). In this study, we validated the original TALK score in our clinical setting and modified the score for Japanese population.
METHODS: The subjects were 21 patients with laryngeal cancer and 50 patients with hypopharyngeal cancer who underwent CCRT at Kobe University Hospital between April 2007 and August 2012. Data regarding T stage, serum albumin level just before treatment, maximum alcohol use, Karnofsky Performance Status (KPS), 3-year overall survival rate and 3-year larynx-preservation rate were collected from medical records. In the revised TALK score (JTALK), the following scoring criteria were modified to adjust Japanese population: T stage of the primary tumor (≥T3), serum albumin level (<3.5 g/dl), maximum alcohol use (≥one 350-ml can of beer/day or an equivalent amount), and KPS (<80%).
RESULTS: The original TALK score was not significantly associated with the larynx preservation rates or survival rates for laryngeal cancer or hypopharyngeal cancer. Instead, JTALK score was significantly associated with the 3-year larynx preservation rates and 3-year survival rates of the patients with hypopharyngeal and laryngeal cancer.
CONCLUSION: These results indicate that JTALK score could be a useful index for predicting the possibility of larynx preservation and prognosis of Japanese patients with advanced laryngeal and hypopharyngeal cancer treated by CCRT.

Entities:  

Keywords:  TALK score; chemoradiotherapy; hypopharyngeal cancer; laryngeal cancer; laryngeal preservation

Mesh:

Year:  2018        PMID: 29955023      PMCID: PMC6192817     

Source DB:  PubMed          Journal:  Kobe J Med Sci        ISSN: 0023-2513


  15 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

Review 2.  Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis.

Authors:  Kyoungjune Pak; Gi Jeong Cheon; Hyun-Yeol Nam; Seong-Jang Kim; Keon Wook Kang; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  J Nucl Med       Date:  2014-04-21       Impact factor: 10.057

3.  Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.

Authors:  Kevin Fung; Teresa H Lyden; Julia Lee; Susan G Urba; Frank Worden; Avraham Eisbruch; Christina Tsien; Carol R Bradford; Douglas B Chepeha; Norman D Hogikyan; Mark E P Prince; Theodoros N Teknos; Gregory T Wolf
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-08       Impact factor: 7.038

4.  Prognostic factor of severe complications in patients with hypopharyngeal cancer with primary concurrent chemoradiotherapy.

Authors:  Liang-Yu Chen; Chia-Chang Huang; Yung-An Tsou; Da-Tian Bau; Ming-Hsui Tsai
Journal:  Anticancer Res       Date:  2015-03       Impact factor: 2.480

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 6.  Branched-chain amino acids as a protein- and energy-source in liver cirrhosis.

Authors:  Hisataka Moriwaki; Yoshiyuki Miwa; Masahiro Tajika; Masahiko Kato; Hideki Fukushima; Makoto Shiraki
Journal:  Biochem Biophys Res Commun       Date:  2004-01-09       Impact factor: 3.575

7.  Genetic polymorphisms of alcohol and aldehyde dehydrogenases, and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell carcinoma.

Authors:  Takahiro Asakage; Akira Yokoyama; Tatsumasa Haneda; Mitsuo Yamazaki; Manabu Muto; Tetsuji Yokoyama; Hoichi Kato; Hiroyasu Igaki; Toshimasa Tsujinaka; Yoshiya Kumagai; Masako Yokoyama; Tai Omori; Hiroshi Watanabe
Journal:  Carcinogenesis       Date:  2006-10-27       Impact factor: 4.944

8.  Biomarkers in advanced larynx cancer.

Authors:  Carol R Bradford; Bhavna Kumar; Emily Bellile; Julia Lee; Jeremy Taylor; Nisha D'Silva; Kitrina Cordell; Celina Kleer; Robbi Kupfer; Pawan Kumar; Susan Urba; Francis Worden; Avraham Eisbruch; Gregory T Wolf; Theodoros N Teknos; Mark E P Prince; Douglas B Chepeha; Norman D Hogikyan; Jeffrey S Moyer; Thomas E Carey
Journal:  Laryngoscope       Date:  2013-07-12       Impact factor: 3.325

9.  Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy.

Authors:  Shang-Wen Chen; Shih-Neng Yang; Ji-An Liang; Fang-Jen Lin; Ming-Hsui Tsai
Journal:  Head Neck       Date:  2009-06       Impact factor: 3.147

10.  Predisposing factors for larynx preservation strategies with non-surgical multimodality treatment for locally advanced (T3-4) larynx, hypopharynx and cervical esophageal disease.

Authors:  Gen Suzuki; Hideya Yamazaki; Etsuyo Ogo; Toshi Abe; Hidehiro Eto; Koichiro Muraki; Chikayuki Hattori; Hirohito Umeno; Norimitsu Tanaka; Toshiaki Tanaka; Satoaki Nakamura; Ken Yoshida
Journal:  Anticancer Res       Date:  2014-09       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.